Typical development cycle of a drug asset
ILC Therapeutics’ initial drug asset is our second-generation hybrid interferon Alfacyte™, which has broad-spectrum antiviral activities, activating a number of antiviral ISGs (interferon-stimulated genes).
Alfacyte™ has been in development for the past five years and has now progressed to pre-clinical and in vivo assessment.
Completion of this stage will allow ILC to progress to clinical trials.
In vitro data for our breakthrough second-generation interferon therapy, Alfacyte™, shows a profile of unmatched antiviral potency.
Alfacyte™ is a novel patented hybrid interferon-alpha with 11 significant amino acid changes in its receptor-binding regions, designed to maximise therapeutic impact.
In vitro tests carried out at the University of St Andrews and our laboratories at BioCity show that Alfacyte™ has 20 times greater antiviral activity than alpha 2a/b or beta interferons.